Abstract: The present invention is broadly directed to a method for reducing autodegradation of activated protein C during processing and purification. The present invention provides aqueous activated protein C solutions and an improved method of processing of such solutions, comprising conducting such processing at an ionic strength of greater than 150 mM and at a pH of about 5.5 to less than 6.3.
Type:
Grant
Filed:
April 24, 1998
Date of Patent:
December 19, 2000
Assignee:
Eli Lilly And Company
Inventors:
Jeffrey Clayton Baker, Andrew David Carlson, Lihua Huang, Theodore Arsay Sheliga
Abstract: The present invention relates to pharmaceutical formulations of activated protein C which also comprises sucrose, sodium chloride and sodium citrate buffer at a pH between about 5.5 and about 6.5. The activated protein C formulations of the present invention are more stable than other formulations of activated protein C and demonstrate fewer degradation products over time.
Type:
Grant
Filed:
April 24, 1998
Date of Patent:
December 12, 2000
Assignee:
Eli Lilly and Company
Inventors:
Andrew David Carlson, Theodore Arsay Sheliga
Abstract: A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surgery, severe trauma, or ARDS, which comprises administering activated protein C providing a highly selective therapeutic agent with a low potential for causing bleeding complications.
Type:
Grant
Filed:
October 8, 1999
Date of Patent:
December 5, 2000
Assignee:
Eli Lilly and Company
Inventors:
Brian William Grinnell, Daniel Lawrence Hartman, Sau-Chi Betty Yan